Stock Comparison

ABBV vs TMDX

AbbVie Inc vs Transmedics Group Inc

The Verdict

TMDX takes this one.

ABBV

AbbVie Inc

0.1

out of 10

Distressed

Winner

TMDX

Transmedics Group Inc

6.8

out of 10

Solid Pick

Head-to-Head

$381.1B

Market Cap

$2.5B

104.8

P/E Ratio

14.8

5.8%

Profit Margin

27.0%

95.6%

Return on Equity

41.9%

20.2

Debt-to-Equity

1.1

Moderate

Overall Risk

Aggressive

0.1

DVR Score

6.8

The Deep Dive

ABBV0.1/10

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Full ABBV Analysis

TMDX6.8/10

Transmedics (TMDX) maintains a compelling long-term thesis driven by its market-leading Organ Care System (OCS) and strategic expansion into integrated organ logistics (NOCS). The Q1 2026 results confirmed robust +21.2% YoY revenue growth, and FY2026 guidance was reiterated, reflecting continued management confidence in the NOCS rollout. However, the Q1 EPS of $0.30 significantly missed consensus ...

Full TMDX Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.